Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Receivables (2016 - 2026)

Orthofix Medical has reported Receivables over the past 17 years, most recently at $137.8 million for Q1 2026.

  • For the quarter ending Q1 2026, Receivables rose 4.48% year-over-year to $137.8 million, compared with a TTM value of $137.8 million through Mar 2026, up 4.48%, and an annual FY2025 reading of $135.7 million, up 0.77% over the prior year.
  • Receivables came in at $137.8 million for Q1 2026, up from $135.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $137.8 million in Q1 2026 to a low of $72.5 million in Q1 2022.
  • Median Receivables over the past 5 years was $125.4 million (2024), compared with a mean of $114.8 million.
  • The sharpest move saw Receivables surged 56.37% in 2023, then grew 0.77% in 2025.
  • Over 5 years, Receivables stood at $82.9 million in 2022, then soared by 54.6% to $128.1 million in 2023, then increased by 5.16% to $134.7 million in 2024, then increased by 0.77% to $135.7 million in 2025, then rose by 1.49% to $137.8 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Receivables are $137.8 million (Q1 2026), $135.7 million (Q4 2025), and $130.8 million (Q3 2025).